Vaccine maker Adimmune Corp (國光生技) on Monday gave an optimistic outlook on sales for this year on expectations of stronger overseas demand for its quadrivalent flu vaccine.
The company said that Flublok, a flu vaccine developed with US-based drug maker Protein Science Corp, has been well received in the US market since its launch last year, and that its distribution partners have increased their orders in anticipation of rising demand.
Adimmune said that since the acquisition of Protein Science by the French multinational pharmaceutical company Sanofi SA in August last year, its new partner has also stepped up distribution and marketing efforts for the vaccine.
Sanofi was encouraged by Flublok’s effectiveness, Adimmune said, adding that the vaccine is manufactured without using eggs to minimize the risk of vaccine resistance as the flu virus mutates.
By contrast, a worse-than-expected outbreak in North America this flu season has diminished physicians’ confidence in competing vaccines, Adimmune said.
The company is ready to meet procurement demands by the WHO and Taiwan’s National Health Insurance Administration, Adimmune said.
It also expects to gain approval to market its flu vaccine to younger people aged 3 to 17.
Meanwhile, the company is set to tap into the veterinary vaccines market through its 51 percent-owned subsidiary, Animmune.
Animmune has inked technology transfer and joint development agreements to partner with the Agricultural Technology Research Institute (農科院) to bring new multivalent swine vaccines to the market by 2022.
At present, farmers have to administer different types of vaccines against porcine circovirus, swine pneumonia and porcine reproductive and respiratory syndrome virus, Adimmune said.
That is a considerable burden on farmers who are raising an estimated 10 million pigs for slaughter at the age of six months.
The new venture aims to develop multivalent vaccines that would eventually tackle two or three of the common infectious diseases, Adimmune said, adding that there are currently no available multivalent in the local market.
The company is planning to introduce its upcoming pig vaccines in Vietnam, the Philippines and Thailand, but not China, because of its protectionist policies.
Adimmune reported a net loss of NT$457 million (US$15.6 million), or loss per share of NT$1.95, in the first nine months of last year.
CHIP RACE: Three years of overbroad export controls drove foreign competitors to pursue their own AI chips, and ‘cost US taxpayers billions of dollars,’ Nvidia said China has figured out the US strategy for allowing it to buy Nvidia Corp’s H200s and is rejecting the artificial intelligence (AI) chip in favor of domestically developed semiconductors, White House AI adviser David Sacks said, citing news reports. US President Donald Trump on Monday said that he would allow shipments of Nvidia’s H200 chips to China, part of an administration effort backed by Sacks to challenge Chinese tech champions such as Huawei Technologies Co (華為) by bringing US competition to their home market. On Friday, Sacks signaled that he was uncertain about whether that approach would work. “They’re rejecting our chips,” Sacks
NATIONAL SECURITY: Intel’s testing of ACM tools despite US government control ‘highlights egregious gaps in US technology protection policies,’ a former official said Chipmaker Intel Corp has tested chipmaking tools this year from a toolmaker with deep roots in China and two overseas units that were targeted by US sanctions, according to two sources with direct knowledge of the matter. Intel, which fended off calls for its CEO’s resignation from US President Donald Trump in August over his alleged ties to China, got the tools from ACM Research Inc, a Fremont, California-based producer of chipmaking equipment. Two of ACM’s units, based in Shanghai and South Korea, were among a number of firms barred last year from receiving US technology over claims they have
It is challenging to build infrastructure in much of Europe. Constrained budgets and polarized politics tend to undermine long-term projects, forcing officials to react to emergencies rather than plan for the future. Not in Austria. Today, the country is to officially open its Koralmbahn tunnel, the 5.9 billion euro (US$6.9 billion) centerpiece of a groundbreaking new railway that will eventually run from Poland’s Baltic coast to the Adriatic Sea, transforming travel within Austria and positioning the Alpine nation at the forefront of logistics in Europe. “It is Austria’s biggest socio-economic experiment in over a century,” said Eric Kirschner, an economist at Graz-based Joanneum
BUBBLE? Only a handful of companies are seeing rapid revenue growth and higher valuations, and it is not enough to call the AI trend a transformation, an analyst said Artificial intelligence (AI) is entering a more challenging phase next year as companies move beyond experimentation and begin demanding clear financial returns from a technology that has delivered big gains to only a small group of early adopters, PricewaterhouseCoopers (PwC) Taiwan said yesterday. Most organizations have been able to justify AI investments through cost recovery or modest efficiency gains, but few have achieved meaningful revenue growth or long-term competitive advantage, the consultancy said in its 2026 AI Business Predictions report. This growing performance gap is forcing executives to reconsider how AI is deployed across their organizations, it said. “Many companies
RSS